An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase IV
Latest Information Update: 23 May 2013
At a glance
- Drugs Bevacizumab; Interferon alpha-2a
- Indications Renal cancer
- Focus Adverse reactions
- Sponsors Roche
- 23 May 2013 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 16 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2012 Actual patients number is 5 as reported by ClinicalTrials.gov.